Table 1. Patient characteristics prior to the start of the study.
| Characteristic | Denosumab monotherapy (n=18) | Combination (n=23) | P-value |
|---|---|---|---|
| Gender (F/M) | 15/3 | 19/4 | |
| Age/years | 72.7±2.4 | 72.7±1.8 | 0.991 2 |
| BMI/(kg·m−2) | 22.5±1.0 | 21.9±0.6 | 0.646 2 |
| Serum corrected Ca | 9.4±0.1 | 9.1±2.1 | 0.100 1 |
| Serum phosphorus | 3.6±0.1 | 3.5±0.2 | 0.494 2 |
| Serum BAP | 16.4±2.0 | 17.2±2.1 | 0.801 6 |
| Serum TRACP-5b | 523.8±60.9 | 528.9±53.5 | 0.950 0 |
| Urinary NTX | 36.5±6.5 | 37.6±4.0 | 0.893 5 |
| 1,25(OH)2D3 | 53.1±4.5 | 54.3±4.6 | 0.853 2 |
| Serum PTH | 25.3±2.8 | 28.3±2.3 | 0.405 3 |
| BP pre-treatment | 8 | 10 | |
| During of BP use, years | 2.1±0.62 | 2.4±0.57 | 0.723 9 |
| L1–4 BMD/(g·cm−2) | 0.793±0.02 | 0.809±0.03 | 0.679 5 |
| Total hip BMD/(g·cm−2) | 0.647±0.02 | 0.689±0.03 | 0.168 1 |
BAP, bone alkaline phosphatase; BMD, bone mineral density; BMI, body mass index; BP, bisphosphonate; NTX, N-terminal telopeptide of type-I collagen; PTH, parathyroid hormone; TRACP-5b, tartrate-resistant acid phosphatase-5b.
Results are the mean±s.e.